Ionis Pharmaceuticals’ year has been defined by sharp contrasts, from fresh FDA approvals to a high profile late stage trial failure that wiped out a chunk of market confidence in a single session. Holding Ionis Pharmaceuticals from the start of the year would have meant a 45.4% loss, including dividends. If you had made that decision on 1 January, would the bullish and bearish research on record at that time have prepared you for how strongly that eplontersen result would test Ionis’ blockbuster ambitions?
This theme extends beyond Ionis Pharmaceuticals. See which of 33 healthcare AI stocks may still merit a closer look.
The Two Futures Ionis Investors Had In Mind
The shares cost US$79.11 at the start of the period, and anyone looking at Ionis Pharmaceuticals then had to choose between two very different stories about what might come next.
On the optimistic side, one set of analysts saw a Fair Value of US$96, a notional destination if their assumptions played out, built on revenue rising 27.7% a year and profit margin shifting from a loss to 19.0% within three years.
On the other hand, the more cautious camp pointed to a Fair Value of US$69.48, tied to revenue growth of 17.3% and a risk that pricing pressure on broader indications would limit how far margins could improve.
What The Results Changed For Ionis Pharmaceuticals
Ionis Pharmaceuticals secured FDA approval for Tryngolza in severe hypertriglyceridemia, supporting the bulls’ focus on bigger indications and new therapies. In the same period, the company faced a sharp setback when the eplontersen Phase 3 trial missed its primary endpoint in ATTR cardiomyopathy, and reported figures showed revenue and profit both fell, with net margin moving from 27.3% to a loss of 42.8%. The evidence cut both ways.
A key assumption investors can test in future situations like Ionis is whether new approvals offset setbacks in profit terms. It may be useful to monitor how total revenue, net income and net margin move after each launch or trial result, and to compare that path with whatever growth and margin profile analysts were using in their original fair value cases.
What Ionis’ Lower Price Now Asks You To Believe
Ionis Pharmaceuticals now trades at US$43.52, well below where the year began. The selected Narrative’s Fair Value sits above the current price and leans on the idea that APOC3 therapies, neurology assets and partnered programs can carry more weight than recent trial setbacks suggest.
On that view, anyone paying today’s price is effectively testing one core belief. The assumption is that Ionis converts broad TRYNGOLZA uptake, progress of ION-775 and ZANVASTRO commercialization into durable revenue and margin gains that justify a higher valuation over time.
"Expanding TRYNGOLZA use in severe hypertriglyceridemia, supported by broad U.S. labeling, enthusiastic physician and payer feedback and a potential patient pool in the millions, can continue to lift revenue growth and improve operating leverage as Ionis Pharmaceuticals scales its commercial infrastructure."
One Narrative disagrees with today's price. → See where this Narrative says Ionis Pharmaceuticals should trade
Go Straight To The Source
Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.
- Company 1 - 48% below our estimate - convert a record backlog of tech-focused builds into recurring service relationships.
- Company 2 - 33% below our estimate - scale newer storage and inverter offerings so partners standardize on one integrated platform.
- Company 3 - 47% below our estimate - channel rising AI infrastructure demand into ad tools that transform campaign targeting and measurement.
That is three of the list. See every one of the 36 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com